Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction
- PMID: 11544314
- DOI: 10.4049/jimmunol.167.6.3266
Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction
Abstract
Fas ligand (L)/CD95L, a proapoptotic member of the TNF family, is a potential target for clinical intervention in various diseases. In the present study, we generated a humanized anti-human FasL mAb and characterized the epitopes of neutralizing mAbs by extensive alanine-scanning mutagenesis of human FasL. The predicted molecular model of FasL trimer revealed that the mAbs recognize largely overlapped conformational epitopes that are composed of two clusters, one around the outer tip-forming D-E loop and another near the top of FasL. Both of these sites on FasL are critically involved in the direct interaction with the corresponding receptor, Fas. These results suggest that the mAbs efficiently neutralize FasL cytotoxicity by masking both of these FasL/Fas contact sites.
Similar articles
-
Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.Clin Exp Immunol. 2002 Aug;129(2):359-69. doi: 10.1046/j.1365-2249.2002.01812.x. Clin Exp Immunol. 2002. PMID: 12165095 Free PMC article.
-
Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling.Biochemistry. 2009 Aug 4;48(30):7251-60. doi: 10.1021/bi900296g. Biochemistry. 2009. PMID: 19588926
-
A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites.Int Immunol. 1998 Feb;10(2):131-40. doi: 10.1093/intimm/10.2.131. Int Immunol. 1998. PMID: 9533440
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
-
Effects of anti-Fas antibodies on lymphocytes and other organs: preparation of original and new monoclonal antibodies and amelioration of systemic autoimmune disease.Int Rev Immunol. 1999;18(4):329-45. doi: 10.3109/08830189909088487. Int Rev Immunol. 1999. PMID: 10626247 Review.
Cited by
-
Precise structural determination of weakly binding peptides by utilizing dihedral angle constraints.J Biomol NMR. 2010 Apr;46(4):299-305. doi: 10.1007/s10858-010-9402-3. Epub 2010 Mar 14. J Biomol NMR. 2010. PMID: 20229289
-
CD95/Fas ligand mRNA is toxic to cells.Elife. 2018 Oct 16;7:e38621. doi: 10.7554/eLife.38621. Elife. 2018. PMID: 30324908 Free PMC article.
-
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.J Virol. 2003 Nov;77(22):12088-104. doi: 10.1128/jvi.77.22.12088-12104.2003. J Virol. 2003. PMID: 14581546 Free PMC article.
-
Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms.J Biol Chem. 2018 Oct 19;293(42):16348-16363. doi: 10.1074/jbc.RA118.004549. Epub 2018 Sep 6. J Biol Chem. 2018. PMID: 30190323 Free PMC article.
-
Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL.Clin Dev Immunol. 2007;2007:93462. doi: 10.1155/2007/93462. Clin Dev Immunol. 2007. PMID: 18317535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous